JAMA Oncology : Association of Measurable Residual Disease With Survival in Patients With Acute Myeloid Leukemia
Interview with Farhad Ravandi, MD, author of Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia: A Systematic Review and Meta-analysis (Source: JAMA Specialty Journals Author Interviews)
Source: JAMA Specialty Journals Author Interviews - October 8, 2020 Category: General Medicine Authors: The JAMA Network Source Type: podcasts

Updated Data on Gilteritinib in AML
Daniel DeAngelo MD, Institute Physician, Professor of Medicine at Harvard Medical School comments on the importance of the updated data on gilteritinib in acute myeloid leukemia (AML). <br /> Author: obr Added: 06/26/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 26, 2019 Category: Cancer & Oncology Source Type: podcasts

Combination Lenalidomide and Azacitidine: A Novel Salvage Therapy in Patients Who Relapse After Allogeneic Stem-Cell Transplantation for Acute Myeloid Leukemia
Charles Craddock MD PhD @charliecraddock of Queen Elizabeth Hospital discusses the Combination Lenalidomide and Azacitidine: A Novel Salvage Therapy in Patients Who Relapse After Allogeneic Stem-Cell ... Author: Annual-Meeting Added: 05/31/2019 (Source: Oncology Tube)
Source: Oncology Tube - May 31, 2019 Category: Cancer & Oncology Source Type: podcasts

Acute Myeloid Leukemia: Incorporating Novel Treatment Approaches into Clinical Pathways
Earn CME credit for this activity: <a target='_blank' href='https://www.naccme.com/program/2018-802-04'>https://www.naccme.com/prog...</a><br /><br />This on-demand webcast examines the latest clinical and pharmacoeconomic data surrounding emerging therapies in AML, in... Author: imedex Added: 03/06/2019 (Source: Oncology Tube)
Source: Oncology Tube - March 6, 2019 Category: Cancer & Oncology Source Type: podcasts

LEAP Consortium In Pediatric Acute Leukemia And Their Efforts
Yana Pikman, M.D. Instructor in Pediatrics, Dana Farber Cancer Institute, Boston Childrens Hospital, Discusses LEAP Consortium In Pediatric Acute Leukemia And Their Efforts At The 60th ASH Annual Mee... Author: obr Added: 01/11/2019 (Source: Oncology Tube)
Source: Oncology Tube - January 11, 2019 Category: Cancer & Oncology Source Type: podcasts

FDA Drug Safety Podcast: FDA warns that symptoms of a serious condition affecting the blood cells are not being recognized with the leukemia medicine Idhifa (enasidenib)
On November 29, 2018 FDA is warning that signs and symptoms of a life-threatening side effect called differentiation syndrome are not being recognized in patients receiving the acute myeloid leukemia medicine Idhifa, active ingredient enasidenib. (Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - December 6, 2018 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts

An exciting development: FLT3 inhibitors as a combination therapy?
While novel FLT3 inhibitors have been, or will be, approved for use as single agents in the treatment of acute myeloid leukemia (AML). Here, Alexander Perl, MD, of the University of Pennsylvania, Phil... Author: VJHemOnc Added: 09/28/2018 (Source: Oncology Tube)
Source: Oncology Tube - September 28, 2018 Category: Cancer & Oncology Source Type: podcasts

Is venetoclax a game changer in AML therapy?
Venetoclax in combination with low intensity chemotherapy for acute myeloid leukemia (AML) in the frontline setting, which although currently under evaluation by the FDA, has shown impressive results.... Author: VJHemOnc Added: 09/28/2018 (Source: Oncology Tube)
Source: Oncology Tube - September 28, 2018 Category: Cancer & Oncology Source Type: podcasts

Overcoming venetoclax resistance in AML with MCL1 inhibition
Venetoclax monotherapy has yielded disappointing results in acute myeloid leukemia (AML) because resistance develops along with the propagation of MCL1-expressing clones. Here, Marina Konopleva, MD, P... Author: VJHemOnc Added: 09/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - September 21, 2018 Category: Cancer & Oncology Source Type: podcasts

Midostaurin and quizartinib: improving survival and day-to-day life in AML
Alexander Perl, MD, of the University of Pennsylvania, Philadelphia, PA, discusses the effectiveness of drugs currently on the market to treat acute myeloid leukemia (AML) at the 2018 Society of Hemat... Author: VJHemOnc Added: 09/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - September 21, 2018 Category: Cancer & Oncology Source Type: podcasts

CAR T-cells in CLL: the current landscape
While CAR T-cells are an approved therapy option in acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL), the research in chronic lymphocytic leukemia (CLL) is somewhat behind.... Author: VJHemOnc Added: 09/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - September 21, 2018 Category: Cancer & Oncology Source Type: podcasts

Venetoclax combinations effective in elderly AML
While venetoclax is widely used in chronic lymphocytic leukemia (CLL) to good effect, previous studies have suggested that the drug does not yield such good results in acute myeloid leukemia (AML). In... Author: VJHemOnc Added: 09/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - September 21, 2018 Category: Cancer & Oncology Source Type: podcasts

Uses of NGS in AML
Christopher Gibson, MD, of Dana-Farber Cancer Institute, Boston, MA, discusses the multiple uses of next-generation sequencing (NGS) in the management of acute myeloid leukemia (AML). Using NGS, clona... Author: VJHemOnc Added: 09/19/2018 (Source: Oncology Tube)
Source: Oncology Tube - September 19, 2018 Category: Cancer & Oncology Source Type: podcasts

MRD testing in acute leukemias
Here, Josep-Maria Ribera, MD, PhD, of Germans Trias i Pujol University Hospital, Barcelona, Spain, discusses the potential of measurable residual disease (MRD) testing to determine treatment outcome i... Author: VJHemOnc Added: 08/31/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 31, 2018 Category: Cancer & Oncology Source Type: podcasts

Changes in the AML treatment landscape
Richard Stone, MD, of the Dana-Farber Cancer Institute, Boston, MA, talks about the latest advances that have been made in acute myeloid leukemia (AML), including recent drug approvals after numerous ... Author: VJHemOnc Added: 08/29/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 29, 2018 Category: Cancer & Oncology Source Type: podcasts